Emcure Pharma IPO, the pharmaceutical company is ready to file its Red Herring Prospectus (RHP) to raise ₹5000 crores through an initial public offering. The IPO will hit the market soon after the Budget in February 2022.
The IPO comprises of a fresh issue of up to ₹1,100 crore, and an offer for sale (OFS) aggregating up to ₹3900 crores by promoter shareholders, founder, CEO and MD Satish Mehta who owns 41.92% and by son Sunil Mehta who holds 6.13%. Other promoter groups/persons who are participating in the OFS collectively own 33.55%, and global private equity major Bain Capital owns 13.09%.
Established in 1983, headquartered at Pune, Emcure Pharma has employees over 11,000 and has two subsidiaries named Zuventus Healthcare and MoreEmcure.The pharmaceutical company has five R&D facilities too and over 350+ brands. The company has its foothold in India as well as a wide network across 70+ countries internationally.
Emcure Pharmaceuticals drives itself with its operations maintaining Quality & patient-focused, integrity, innovation, teamwork, and value-driven. Emcure is one of the market leaders in HIV antivirals, gynaecology, and blood-related therapeutic areas. According to Crisil’s report, the company had a domestic market share of 51.53%, 11.85%, and 10.26%, respectively, as of March 2021.
Emcure’s product portfolio includes orals, injectables, and biologics, the mRNA platform through which it is developing the Covid-19 vaccine, which has enabled it to reach over 70 countries having a strong presence in Europe and Canada. The company is among the top 12 pharma companies in India.
Objectives of Emcure Pharma IPO
- The company will utilize funds from the proceeds to repay/prepay debt which as of March 2021 stood at Rs 1,252.6 crore.
- General corporate purposes.
Emcure Pharma IPO Promoters
- Satish Mehta.
- Sunil Mehta.
- Bain Capital.
Company Financials
| Emcure Pharma | FY21 | FY20 | FY19 |
| Revenue | ₹6,091.8 crores | ₹5,130.8 crores | ₹4,815.6 crores |
| Net Income | ₹418.6 crores | ₹100.6 crores | ₹202.9 crores |
Emcure Pharma IPO Details
| IPO Details | Emcure Pharma |
| Issue Period | Opening Date: xx-02-2022 Closing Date: xx-02-2022 |
| Price Band | ₹ – ₹ per equity share |
| Issue Size | ₹5000 Cr |
| Face Value | ₹- per equity share |
| Issue Type | Book built issue |
| Fresh Issue | [.] Eq Shares of ₹- face value (aggregating up to ₹1100 Cr) |
| Offer for sale | [.] Eq Shares of ₹- face value (aggregating up to ₹3900 Cr) |
| Listing | NSE and BSE |
| Registrar | – |
Emcure Pharma IPO Timeline
Emcure Pharma IPO issue date, issue price, allotment date, the listing date, and all the details will be announced soon.
| IPO Opens | To be announced |
| IPO Ends | To be announced |
| Allotment Begins | To be announced |
| Refund Initiation | To be announced |
| Allotment Date | To be announced |
| Listing Date | To be announced |
Emcure Pharma IPO Lot Size (Retail Individual Investors)
| Applications | Lots | Shares | Amount(Cut-off) |
| Minimum | – | – | – |
| Maximum | – | – | – |
Emcure Pharma IPO Investor Category
Emcure Pharma IPO has [.] of the net offer under the Retail Category.
| QIB (Qualified Institutional Buyers) | – |
| NII (Non-Institutional Investors) | – |
| RII (Retail Individual Investors) | – |
Emcure Pharma IPO GMP
Emcure Pharma IPO has not yet started trading in the grey market. Currently, the Emcure Pharma grey market premium is zero and will be updated once it starts trading in the grey market.
Emcure Pharma IPO Review
In FY21, 64.75% of its domestic sales came from chronic therapeutics compared to 53.26% for the industry. Seven of its brands featured among the top 300 brands for the same period. Currently, no reviews are available. A detailed review will be updated soon once its price band and valuations are made public.
Emcure Pharma Book Running Lead Manager(s)
- Axis Capital Limited.
- Bank of America Securities India.
- JM Financial.
- Bob Caps.
Company Contact Details
Emcure Pharmaceuticals Limited
Plot P-II, IT-BT Park,
M.I.D.C., Hinjawadi,
Pune- 411 057
E-mail: apisales@emcure.co.in
Phone: 020-39821300
Website: www.emcure.com